Status:
UNKNOWN
Impact of Therapeutic Plasma Exchange on RNA Biomarker Expression Levels in Alzheimer's Patients
Lead Sponsor:
MaxWell Clinic, PLC
Conditions:
Alzheimer Disease
Eligibility:
All Genders
18+ years
Brief Summary
The study will determine if Therapeutic Plasma Exchange removes RNA biomarkers associated with Alzheimer's Disease and how quickly those biomarkers reappear after treatment.
Detailed Description
Participants with a diagnosis of Alzheimer's or Mild Cognitive Impairment will undergo therapeutic plasma exchange as part of their treatment for the disease as per the AMBAR Trial protocol. Patients ...
Eligibility Criteria
Inclusion
- Subject is scheduled to undergo their first TPE Procedure for a diagnosis of Alzheimer's Disease or previous mental/cognitive impairment
- Mentally capable of understanding and completing informed consent for the study.
Exclusion
- Subject is unable or failed to return/provide blood specimen on days seven (7), fourteen (14) , twenty-one (21), and twenty-eight (28) (plus or minus 1 day on follow up draws) post plasma exchange
- Subject is unable to provide informed consent.
Key Trial Info
Start Date :
March 22 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT06079827
Start Date
March 22 2022
End Date
September 1 2025
Last Update
October 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The MaxWell Clinic
Brentwood, Tennessee, United States, 37027